Gall Matthew
SEC insider (Form 3/4/5 filer). CIK 0001816194. Chief Financial Officer at Tango Therapeutics, Inc. (TNGX) and 2 other issuers. 11 reported Form 4/5 transactions since Sep 2024; latest on May 1, 2026. Located in BERKELEY HEIGHTS, NJ.
Companies Gall Matthew has filed insider reports for
- Tango Therapeutics, Inc. (TNGX): Officer, Chief Financial Officer
- Kalaris Therapeutics, Inc. (KLRS): Officer, Chief Financial Officer
- iTeos Therapeutics, Inc. (ITOS): Officer, Chief Financial Officer
Gall Matthew
CIK: 0001816194
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- May 1, 2026TNGX
Tango Therapeutics, Inc.
AwardDirect40K shares- - Mar 19, 2026KLRS
Kalaris Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
95K shares- - Nov 3, 2025KLRS
Kalaris Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
235K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
252.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
8.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Tender OfferDirect89.4K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
9.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
135.9K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
42.4K shares- - Mar 7, 2025ITOS
iTeos Therapeutics, Inc.
AwardDirect24K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 1, 2026 |  TNGX Tango Therapeutics, Inc. | Award | 40,000 | - | $0 | Direct |
| Mar 19, 2026 |  KLRS Kalaris Therapeutics, Inc. | Award Stock Option (Right to Buy) | 95,000 | - | - | Direct |
| Nov 3, 2025 | KLRS Kalaris Therapeutics, Inc. | Award Stock Option (Right to Buy) | 235,000 | - | - | Direct |
| Aug 29, 2025 |  ITOS iTeos Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 252,135 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 8,123 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Tender Offer | 89,429 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 9,063 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 135,937 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 42,388 | - | - | Direct |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | Award | 24,000 | - | - | Direct |
1-10 of 11 transactions